Literature DB >> 26477323

Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing's disease: A single-center study.

Shozo Yamada1, Naoko Inoshita, Noriaki Fukuhara, Mitsuo Yamaguchi-Okada, Hiroshi Nishioka, Akira Takeshita, Hisanori Suzuki, Junko Ito, Yasuhiro Takeuchi.   

Abstract

This study aimed to investigate early and late outcomes of patients who underwent neurosurgical procedures for the preoperative diagnosis of Cushing's disease (CD). Clinical, endocrine, imaging, and histologic data from 252 patients undergoing pituitary surgery at Toranomon Hospital through the end of 2012 were entered into a database and statistically analyzed. In 22 of these patients (8.7%; positive venous sampling in 15 and negative venous sampling in 7 patients), tumors were invisible on magnetic resonance imaging (MRI) and 42.9% of them achieved remission. In the remaining 230 patients, 93.5% of those with microadenomas (n=154) and 71.1% of those with macroadenomas (n=76) achieved early postoperative remission, with recurrence rates of 2.7% and 14.8%, respectively, during a 72.5-month median follow-up. In multivariate analyses, cavernous sinus invasion (CSI; odds ratio [OR], 13.0), type of surgery (OR, 4.0), and tumor size (OR, 2.7) were significant preoperative factors affecting early postoperative results, whereas peak cortisol levels ≥9.4 μg/dL in response to corticotropin-releasing hormone (CRH) and CSI were significant factors predicting recurrence. Tumor recurrence was more common in patients with non-densely granulated adenomas than in patients with densely granulated adenomas. We propose that the higher remission and lower recurrence rates in this series are due to our surgical strategies, including extracapsular tumor removal, aggressive resection of tumors with CSI, extended transsphenoidal surgery (TSS), or a combined approach for large/giant adenomas. Appropriate multimodal treatments, including radiotherapy, medication, and repeated surgery in patients with persistent or recurrent CD, could result in better overall outcomes than previously achieved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26477323     DOI: 10.1507/endocrj.15-0463

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

Review 1.  The experience with transsphenoidal surgery and its importance to outcomes.

Authors:  Jürgen Honegger; Florian Grimm
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

2.  Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series.

Authors:  A L Serban; G Del Sindaco; E Sala; G Carosi; R Indirli; G Rodari; C Giavoli; M Locatelli; G Carrabba; G Bertani; G Marfia; G Mantovani; M Arosio; E Ferrante
Journal:  J Endocrinol Invest       Date:  2019-11-26       Impact factor: 4.256

Review 3.  Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.

Authors:  Ashley B Grossman; Shereen Ezzat; Sylvia L Asa; Ozgur Mete; Michael D Cusimano; Ian E McCutcheon; Arie Perry; Shozo Yamada; Hiroshi Nishioka; Olivera Casar-Borota; Silvia Uccella; Stefano La Rosa
Journal:  Mod Pathol       Date:  2021-05-21       Impact factor: 7.842

Review 4.  Outcome of endoscopic vs microsurgical transsphenoidal resection for Cushing's disease.

Authors:  Nidan Qiao
Journal:  Endocr Connect       Date:  2018-01       Impact factor: 3.335

Review 5.  Recent Evolution of Endoscopic Endonasal Surgery for Treatment of Pituitary Adenomas.

Authors:  Hiroshi Nishioka
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-02-24       Impact factor: 1.742

Review 6.  Invasive ACTH-secreting pituitary macroadenoma in remission after transsphenoidal resection: A case report and literature review.

Authors:  Zhe Zhuang; Xiaohai Liu; Xinjie Bao; Boju Pan; Kan Deng; Yong Yao; Wei Lian; Bing Xing; Huijuan Zhu; Lin Lu; Renzhi Wang; Ming Feng
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

7.  Usefulness of desmopressin testing to predict relapse during long-term follow-up in patients in remission from Cushing's disease.

Authors:  Alberto Giacinto Ambrogio; Massimiliano Andrioli; Martina De Martin; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Endocr Connect       Date:  2017-10-10       Impact factor: 3.335

8.  Optimizing MR imaging for intraoperative image guidance in sellar pathologies.

Authors:  Alexander Micko; Arthur Hosmann; Wolfgang Marik; Sophie Bartsch; Michael Weber; Engelbert Knosp; Stefan Wolfsberger
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

9.  Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.

Authors:  Tomoko Mizuno; Naoko Inoshita; Noriaki Fukuhara; Keita Tatsushima; Akira Takeshita; Shozo Yamada; Hiroshi Nishioka; Yasuhiro Takeuchi
Journal:  Intern Med       Date:  2021-08-31       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.